RAPT Therapeutics, Inc. (RAPT) Free Cash Flow (2020 - 2024)
RAPT Therapeutics (RAPT) has disclosed Free Cash Flow for 5 consecutive years, with -$10.4 million as the latest value for Q4 2024.
- Quarterly Free Cash Flow rose 62.48% to -$10.4 million in Q4 2024 from the year-ago period, while the trailing twelve-month figure was -$83.4 million through Dec 2024, up 15.03% year-over-year, with the annual reading at -$83.4 million for FY2024, 15.03% up from the prior year.
- Free Cash Flow hit -$10.4 million in Q4 2024 for RAPT Therapeutics, up from -$17.6 million in the prior quarter.
- In the past five years, Free Cash Flow ranged from a high of -$6.4 million in Q2 2020 to a low of -$29.0 million in Q2 2023.
- Historically, Free Cash Flow has averaged -$17.8 million across 5 years, with a median of -$16.5 million in 2022.
- Biggest five-year swings in Free Cash Flow: plummeted 117.52% in 2021 and later skyrocketed 62.48% in 2024.
- Year by year, Free Cash Flow stood at -$15.5 million in 2020, then crashed by 35.62% to -$21.1 million in 2021, then fell by 8.65% to -$22.9 million in 2022, then decreased by 21.5% to -$27.8 million in 2023, then surged by 62.48% to -$10.4 million in 2024.
- Business Quant data shows Free Cash Flow for RAPT at -$10.4 million in Q4 2024, -$17.6 million in Q3 2024, and -$28.2 million in Q2 2024.